South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday it had launched its botulinum toxin product Nabota in Germany and Austria through its overseas partner Evolus Inc., a US performance beauty company.
This is the second European launch for Nabota, which is sold under the brand name Nuceiva outside Asia, after the UK in September last year. Germany is the second-largest market for botulinum toxin products in the European Union, with an annual market size of 100 billion won ($76 million).
Evolus has teamed up with Novia GmbH, a local distributor of cosmetic medical products in Germany and Austria, to market Nabota since mid-February.
Daewoong Vice President Park Sung-soo said the launch would help Nabota gain recognition and market share in the EU market and showcase the product’s capabilities as a Korean-made botulinum toxin product.
Nabota, which was developed and manufactured by Daewoong, is the only botulinum toxin product from Korea and Asia that has received approval from the US Food and Drug Administration.
As of Feb. 2023, Nabota has been approved by regulators in more than 60 countries and exported to more than 80 countries.
Write to Jung-Eun Kim at
likesmile@hankyung.com